Payment overview · 2025
General Payments
$501.19
14 reported records · 8 companies
Healthcare provider profile · identity verified
Shari B Rosenbaum, MD
Allopathic & Osteopathic Physicians|Internal Medicine · BOCA RATON, FL · NPI 1750307823
Verified facts
What the public records show
CMS Open Payments records show Shari B Rosenbaum, MD received $501.19 in general payments during 2025 across 14 reported records.
Sonex Health, Inc. accounted for 31.5% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 11 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Mounjaro, Wegovy.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 47708 records involving 23833 distinct recipient NPIs. Public Medicare Part D data also shows 14 claims for Jardiance by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported MOUNJARO as an associated drug or biological on 186719 records involving 66436 distinct recipient NPIs. Public Medicare Part D data also shows 60 claims for Mounjaro by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 20 claims for Ozempic by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Wegovy as an associated drug or biological on 183056 records involving 75256 distinct recipient NPIs. Public Medicare Part D data also shows 15 claims for Wegovy by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| Sonex Health, Inc. | Unresolved — no canonical attribution shown | $157.67 | 31.5% | 1 | 2025 |
| Lilly USA, LLC | Unresolved — no canonical attribution shown | $84.02 | 16.8% | 4 | 2025 |
| Saluda Medical Americas, Inc. | Unresolved — no canonical attribution shown | $72.91 | 14.6% | 1 | 2025 |
| GlaxoSmithKline, LLC. | Unresolved — no canonical attribution shown | $48.83 | 9.7% | 2 | 2025 |
| Novartis Pharmaceuticals Corporation | Unresolved — no canonical attribution shown | $43.80 | 8.7% | 2 | 2025 |
| Medicure Pharma Inc. | Unresolved — no canonical attribution shown | $38.38 | 7.7% | 1 | 2025 |
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $35.01 | 7.0% | 2 | 2025 |
| Amgen Inc. | Unresolved — no canonical attribution shown | $20.57 | 4.1% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $501.19 | 14 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| SX-ONE MICROKNIFE Normalized: sx one microknife |
Device | Sonex Health, Inc. | $157.67 | 1 | 2025 |
Source payment records
|
|||||
| MOUNJARO Normalized: mounjaro |
Drug | Lilly USA, LLC | $84.02 | 4 | 2025 |
Source payment records
|
|||||
| ZEPBOUND Normalized: zepbound |
Drug | Lilly USA, LLC | $84.02 | 4 | 2025 |
Source payment records
|
|||||
| Evoke Normalized: evoke |
Device | Saluda Medical Americas, Inc. | $72.91 | 1 | 2025 |
Source payment records
|
|||||
| AREXVY Normalized: arexvy |
Biological | GlaxoSmithKline, LLC. | $48.83 | 2 | 2025 |
Source payment records
|
|||||
| SHINGRIX Normalized: shingrix |
Biological | GlaxoSmithKline, LLC. | $48.83 | 2 | 2025 |
Source payment records
|
|||||
| LEQVIO Normalized: leqvio |
Drug | Novartis Pharmaceuticals Corporation | $43.80 | 2 | 2025 |
Source payment records
|
|||||
| Zypitamag Normalized: zypitamag |
Drug | Medicure Pharma Inc. | $38.38 | 1 | 2025 |
Source payment records
|
|||||
| Wegovy Normalized: wegovy |
Drug | Novo Nordisk Inc | $35.01 | 2 | 2025 |
Source payment records
|
|||||
| OTEZLA Normalized: otezla |
Drug | Amgen Inc. | $20.57 | 1 | 2025 |
Source payment records
|
|||||
| REPATHA Normalized: repatha |
Biological | Amgen Inc. | $20.57 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| MOUNJARO mounjaro |
2025 | Mounjaro | 2024 | 60 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| Wegovy wegovy |
2025 | Wegovy | 2024 | 15 Beneficiary count suppressed |
exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 47708 supporting records · 23833 recipient NPIs · example record 1186464557 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
14 | suppressed by CMS |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | MOUNJARO open payments reported associated product |
CMS Open Payments — General Payments 186719 supporting records · 66436 recipient NPIs · example record 1186464455 |
Mounjaro · 2024 Exact normalized brand match · 1 Part D row |
60 | suppressed by CMS |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
20 | suppressed by CMS |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Wegovy open payments reported associated product |
CMS Open Payments — General Payments 183056 supporting records · 75256 recipient NPIs · example record 1188130070 |
Wegovy · 2024 Exact normalized brand match · 1 Part D row |
15 | suppressed by CMS |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Rosuvastatin Calcium | Rosuvastatin Calcium | 239 | 85 |
| Atorvastatin Calcium | Atorvastatin Calcium | 203 | 76 |
| Amlodipine Besylate | Amlodipine Besylate | 141 | 49 |
| Levothyroxine Sodium | Levothyroxine Sodium | 115 | 41 |
| Ezetimibe | Ezetimibe | 109 | 39 |
| Losartan Potassium | Losartan Potassium | 106 | 39 |
| Escitalopram Oxalate | Escitalopram Oxalate | 105 | 39 |
| Metformin Hcl | Metformin Hcl | 83 | 29 |
| Pantoprazole Sodium | Pantoprazole Sodium | 79 | 37 |
| Lisinopril | Lisinopril | 67 | 17 |
| Metoprolol Succinate | Metoprolol Succinate | 65 | 20 |
| Repatha Sureclick | Evolocumab | 63 | 17 |
| Mounjaro | Tirzepatide | 60 | suppressed |
| Alprazolam | Alprazolam | 58 | 31 |
| Synthroid | Levothyroxine Sodium | 55 | 18 |
| Famotidine | Famotidine | 53 | 24 |
| Omeprazole | Omeprazole | 49 | 18 |
| Trazodone Hcl | Trazodone Hcl | 49 | 20 |
| Duloxetine Hcl | Duloxetine Hcl | 46 | 16 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 42 | 15 |
| Montelukast Sodium | Montelukast Sodium | 42 | 25 |
| Cefuroxime | Cefuroxime Axetil | 41 | 30 |
| Zolpidem Tartrate | Zolpidem Tartrate | 37 | 22 |
| Azithromycin | Azithromycin | 33 | 29 |
| Methylprednisolone | Methylprednisolone | 33 | 29 |
| Clopidogrel | Clopidogrel Bisulfate | 31 | 11 |
| Hydrochlorothiazide | Hydrochlorothiazide | 31 | 11 |
| Citalopram Hbr | Citalopram Hydrobromide | 30 | suppressed |
| Furosemide | Furosemide | 29 | 11 |
| Simvastatin | Simvastatin | 29 | suppressed |
| Pravastatin Sodium | Pravastatin Sodium | 28 | 12 |
| Tamsulosin Hcl | Tamsulosin Hcl | 28 | 12 |
| Temazepam | Temazepam | 28 | 12 |
| Cephalexin | Cephalexin | 27 | 24 |
| Eliquis | Apixaban | 27 | 12 |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 26 | 24 |
| Bupropion Xl | Bupropion Hcl | 26 | suppressed |
| Clonazepam | Clonazepam | 26 | suppressed |
| Alendronate Sodium | Alendronate Sodium | 24 | suppressed |
| Allopurinol | Allopurinol | 24 | suppressed |
| Pregabalin | Pregabalin | 24 | suppressed |
| Lactulose | Lactulose | 23 | suppressed |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 23 | 19 |
| Diazepam | Diazepam | 22 | 13 |
| Fluoxetine Hcl | Fluoxetine Hcl | 22 | suppressed |
| Praluent Pen | Alirocumab | 22 | suppressed |
| Amitriptyline Hcl | Amitriptyline Hcl | 21 | suppressed |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 21 | suppressed |
| Finasteride | Finasteride | 21 | suppressed |
| Ozempic | Semaglutide | 20 | suppressed |
| Valacyclovir | Valacyclovir Hcl | 20 | 12 |
| Atenolol | Atenolol | 18 | suppressed |
| Azelastine Hcl | Azelastine Hcl | 18 | suppressed |
| Livalo | Pitavastatin Calcium | 18 | suppressed |
| Meloxicam | Meloxicam | 18 | suppressed |
| Ramipril | Ramipril | 18 | suppressed |
| Sertraline Hcl | Sertraline Hcl | 18 | suppressed |
| Valsartan | Valsartan | 17 | suppressed |
| Torsemide | Torsemide | 16 | suppressed |
| Metoprolol Tartrate | Metoprolol Tartrate | 15 | suppressed |
| Wegovy | Semaglutide | 15 | suppressed |
| Dexlansoprazole Dr | Dexlansoprazole | 14 | suppressed |
| Jardiance | Empagliflozin | 14 | suppressed |
| Anoro Ellipta | Umeclidinium Brm/Vilanterol Tr | 13 | suppressed |
| Buspirone Hcl | Buspirone Hcl | 13 | suppressed |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 13 | suppressed |
| Lidocaine | Lidocaine | 13 | suppressed |
| Ondansetron Odt | Ondansetron | 13 | suppressed |
| Viberzi | Eluxadoline | 13 | suppressed |
| Carvedilol | Carvedilol | 12 | suppressed |
| Mometasone Furoate | Mometasone Furoate | 12 | suppressed |
| Spironolactone | Spironolactone | 12 | suppressed |
| Doxycycline Hyclate | Doxycycline Hyclate | 11 | suppressed |
| Linzess | Linaclotide | 11 | suppressed |
| Myrbetriq | Mirabegron | 11 | suppressed |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 11 | suppressed |
| Telmisartan | Telmisartan | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $501.19 · 14 records | Sonex Health, Inc. | AREXVY, Evoke, LEQVIO, MOUNJARO, OTEZLA, REPATHA, SHINGRIX, SX-ONE MICROKNIFE, Wegovy, ZEPBOUND, Zypitamag | 4 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Mounjaro play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with Lilly USA, LLC?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error